Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

In a significant step toward improving targeted cancer therapy, researchers from Japan have developed a novel nanocarrier ...

How is antibody-drug conjugate (ADC) development impacting oncology? Key Takeaways Recent innovations across the multiple ADC components are critical to improving the therapeutic window as we advance ...

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendritic cell neoplasm ...

Site-selective modifications of proteins, without compromising their biological activity, are highly sought after due to their critical role in many biomedical applications. Here, we established a ...

Innovative antibody drug conjugates are advancing in ovarian cancer treatment, exploring new maintenance therapies and biomarker-driven approaches for improved outcomes.

A TROP2-directed antibody-drug conjugate, DB-1305/BNT325, demonstrated durable activity in patients with previously treated ovarian cancer.

Cantargia Presents Promising Preclinical Results on Anti-IL1RAP Antibody-Drug Conjugate (ADC) at a Major Cancer Conference Provided by Accesswire Apr 25, 2025, 10:15:00 AM ...

Poster number: 2875 Poster title: IL1RAP-targeting antibody-drug conjugate: A novel therapeutic targeting both tumor cells and the tumor microenvironment. Session date: April 28, 2025 The poster will ...

The first antibody-drug conjugate in this space was [Kadcyla], which quickly became the standard of care in third-line and second-line metastatic HER2-positive breast cancer. However, it did not ...

World revenue for the Antibody Drug Conjugates Market is set to surpass US$16 billion in 2025, with strong revenue growth through to 2035.

Background: Antibody-drug conjugate (ADC) is an anticancer drug that links toxins to specifically targeted antibodies via linkers, offering the advantages of high target specificity and high ...